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Abstract. We evaluated the occurrence of mutations in P53, K-RAS, COX-2, expression of COX-2 and hTERT and relations
among clinicopathological signs. P53 mutations were identified in 34.4% of tumours, the majority of them occurring in SCC
(squamous cell carcinoma, 55.6%). K-RAS was mutated in 12.2% of NSCLC tumours, the majority of the mutations being
found in ADC (adenocarcinoma, 27.0%). Mutational screening detected three different COX-2 mutations and five different P53
mutations, published for the first time. With RT-PCR we observed that the expression of the tested genes, hTERT and COX-2,
was highly significant for ADC (p < 0.01) and SCC (p < 0.05). Statistical analysis of the combined results revealed significant
correlation between expression of COX-2 and hTERT (p < 0.001), hTERT expression and staging (p < 0.05) and survival (p <
0.01). A positive correlation between COX-2 expression and K-RAS mutation (p < 0.05) was also observed. This study provides
insight into associations between the analysed biomarkers and the clinical-pathological data of the patients.
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1. Introduction
Non-small-cell lung cancer (NSCLC) includes ade-
nocarcinoma (ADC), squamous cell carcinoma (SCC)
and large cell carcinoma (LCC), types of lung cancer
with similar clinical and biological characteristics [1,2].
Different types of NSCLC are the result of carcinogen-
esis in different types of cells, which undergo stepwise
malignant progression because of the accumulation of
genetic alterations [2].
Various genes that undergo genetic alterations in
lung cancer cells have so far been identified. The most
frequently described mutated genes are P53 (alter-
ations have been detected in∼50% of NSCLC) and
K-RAS (alterations have been detected in∼15% of
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NSCLC) [2]. Defects in P53 are common in NSCLC,
suggesting that this pathway is essential for the regu-
lation of growth, differentiation and death of lung ep-
ithelial cells [1,3]. Alterations of the RAS genes (mu-
tations occur mainly on K-RAS and account for∼90%
of RAS mutations in NSCLC, predominantly in ADC)
play an essential role in signal transduction instability
and can consecutively cooperate in lung tumourigene-
sis [2,4]. It has generally been accepted that mutations
in either P53 or K-RAS or both may be of prognostic
significance in early stage NSCLC [5,6].
The search for prognostic factors in NSCLC has ex-
panded over the years from mutation detection to gene
expression detection. Telomerase can be expressed in
up to 85% of NSCLC and thus plays a critical role
in maintaining cellular immortality [7–9]. Positive
hTERT expression has been significantly associated
with worse survival [7–9]. It has also been pub-
lished that a combination of P53 mutation and telom-
erase over-expression may induce tumourigenesis in
NSCLC [10,11]. There is multiple evidence of elevated
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COX-2 levels in NSCLC and their importance in lung
carcinogenesis [12–14]. Over-expression of COX-2
has been proposed as a biomarker for biologically ag-
gressive types of NSCLC and poorer survival [15–17].
Some publications have statistically evaluated the com-
bination of more than one prognostic factor for gaining
higher statistical power and/or researching the correla-
tion between two or more independent factors. It has
been shown that combined analysis of COX-2 and P53
expression or P53 gene mutation and telomerase activi-
ty may be useful for identifying the severity of NSCLC
and the patient’s prognosis [10,18].
In this study, we examined possible relationships
between somatic mutations in P53, K-RAS and COX-2
and expression levels in COX-2 and hTERT, in order
to investigate the specific associations between these
alterations and clinical data in NSCLC overall and in
all three types of NSCLC separately.
2. Material and methods
2.1. Patients
The examined NSCLC patient group consisted of 75
(83.3%) males and 15 (16.7%) females, with ages rang-
ing from 48 to 83 years (mean± standard deviation;
65.4± 9.1 years, data shown in Table 1). Seventy-
eight out of 90 patients stated that they were smokers
(86.7%), of which 67 were male (89.3%) and 11 female
(73.3%). The median follow–up of the patients was 8.9
years (from 7.7 to 14.8 years). Patients who died during
the study were considered to have been followed until
the end of the study. To our knowledge, patients were
not chronically subjected to any other environmental
exposure known to promote the development of lung
cancer (uranium or coal mines; asbestos, mustard gas
or radon exposure). The National Medical Ethics Com-
mittee of the Republic of Slovenia (NMEC) approved
the study. Our analysis included 90 surgical specimens
of patients with primary non-small cell lung carcinoma
(34 adenocarcinoma, 45 squamous cell carcinoma, 11
large cell carcinoma, data shown in detail in Table 1).
Lung resectates were examined by an expert patholo-
gist. Adjacent macroscopically normal lung tissue was
obtained several cm from the tumour whenever possi-
ble and used as a control. All samples were snap-frozen
in liquid nitrogen and stored at−80◦ C until RNA and
DNA isolation.
2.2. DNA extraction and mutation detection
DNA was extracted from snap frozen lung can-
cer tumours and corresponding normal tissue using
NucPrepTM chemistry (Applied Biosystems, Foster
city, CA, USA) on ABI 6100 (Applied Biosystems,
Foster city, CA, USA). P53, K-RAS and COX-2 mu-
tational status was determined by denaturising high-
pressure liquid chromatography (DHPLC) mutation
analysis (Transgenomic, USA). For DHPLC of the P53
gene, primers and conditions were used as described
previously [19]. For DHPLC screening of K-RAS mu-
tational hotspots in exons one and two, primers pub-
lished by Konig et al. were used [20] and column tem-
perature was calculated with WavemakerTM.
Newly designed primers (Table 2), suitable for DH-
PLC mutation detection for COX-2 gene, were cho-
sen with an online oligo-designer (IDTSCITools Oli-
go Design and Analysis), and the conditions for DH-
PLC mutation screening were selected according to
WavemakerTM (Transgenomic, USA).
2.3. RNA extraction, cDNA synthesis and gene
expression detection
RNA for the expression analysis was extracted with
TRIzol reagent and chloroform. After extraction,
total RNA was cleaned with PurelinkTM Micro-to-
Midi System (Invitrogen,ZDA). First strand cDNA was
synthesized using MultiScribeTM reverse transcriptase
(Applied BioSystems, Foster City, California, USA),
with random hexamers, according to the manufactur-
er’s instructions.
Expression of the COX-2 and hTERT genes in tu-
mours relative to their normal adjacent tissues was
measured using quantitative real–time PCR (RT-PCR)
based on the TaqMan fluorescence methodology.
A ready mixture of probes and primers specific for
COX-2 (Assay-on-DemandTM, Hs0015133m1; Ap-
plied Biosystems, Foster City, USA) and hTERT
(Assay-on-DemandTM, Hs99999022m1; Applied
Biosystems, Foster City, USA) expression and human
18S rRNA as the endogenous control gene were used
(TaqMan pre-developed assay reagents for gene ex-
pression; Applied BioSystems). The relative quantifi-
cation of mRNA levels of the target genes (quantity
of transcripts of the target in tumours relative to nor-
mal tissues) was determined using the∆∆CT (∆CT
tumour-∆CT normal) method. If∆∆CT was signif-
icantly higher or lower than zero, the expression was
considered to be statistically significantly over or under
expressed.
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Table 1
Data showing histological (locations of the tumours, pTNM) and clinical (survival, age at the diagnosis, gender distribution)
data of patients whose tumour samples were used in this study (NSCLC – non-small cell lung cancer, ADC – adenocarcinoma,
LCC – large cell carcinoma, SCC – squamous cell lung carcinoma, vs. – versus,∗classified according to the American Joint
Committee for Cancer Staging System)
Non-small cell lung cancer types
ADC LCC SCC NSCLC
Percentage of samples (%) 37.8 12.2 50.0 100
Average age at diagnosis (years) 65.5 (SD± 9.6) 62.9 (SD± 14.4) 65.9 (SD± 8.3) 65.4 (SD± 9.1)
Survival (months) 32.4 (SD± 27.0) 8.4 (SD± 7.4) 33.4 (SD± 26.4) 30.5 (SD± 26.5)
Males against this type of NSCLC (%) 61.8 90.9 97.8
Males against all NSCLC (%) 23.3 11.1 48.9
Males against males all NSCLC (%) 28.0 13.3 58.7
Females against this type of NSCLC (%) 38.2 9.1 2.2
Females against all NSCLC (%) 14.4 1.1 1.1
Females against females all NSCLC (%) 86.6 6.7 6.7
Location of the tumour in the lungs (number of samples)
Bronchus 0 0 2 2
Upper lobe 19 7 21 47
Middle lobe 2 0 4 6
Lower lobe 10 4 16 30
Overgrown lesion 1 0 0 1
Not defined 2 0 2 4
Stage grouping from pTNM* (number of samples)
IA 4 1 6 11
IB 10 5 21 36
IIA 2 0 4 6
IIB 7 0 6 13
IIIA 6 3 8 17
IIIB 3 0 0 3
IV 2 2 0 4
Table 2
Primers used for genomic DHPLC analysis, oligonucleotide sequences of PCR primers, PCR product lengths and annealing
temperatures for COX-2 gene
Exon 5’ Forward primers 5’ Reverse primers Length (bp) Annealing T (◦C)
EX1+UTR AGGCGGAAAGAAACAGTCA GGAGGTCAGAGCGGAAACT 336 57
EX2+3 TGATTTATTTGCTGTCCT CTGTATAAACTGGATGGG 593 48
EX4 CTCAGGTGCCACTTTCCA CAATGCAGCCCGTCTTAT 293 50
EX5 GATTCTTACCTTAGCTTTCT TAATGTTAGCCCTTGACT 278 48
EX6+7 AAACTTCAACAGCAACAA TTTTCATTTACCACATCT 596 47
EX8 ATTGCATTCCAGTTGCTT GTCTTTTGTTTTGGTTTTCA 394 48
EX9 CCTAAGGCAAGCTGAATA GAAGTTGAGGCAGGAGAA 398 50
EX10 CTGTCTTCATCGCCTTCA GACTCCTTTCTCCGCAAC 571 51
2.4. Statistics
Survival was examined using the Kaplan-Meier
method and variable effects on survival time were an-
alyzed using Cox’s regression model. Magnitudes and
directions of the associations between intervals or ra-
tio scale variables were determined using Spearman’s
Rho non-parametric test and comparisons between two
independent samples with the Mann-Whitney U test,
as appropriate. We used the Chi-square test for deter-
mining the association between mutations in K-RAS
and P53 and ESE motifs. Differences were consid-
ered significant atp < 0.05. For statistical evaluation
of the alteration abundances, we used the Fisher’s ex-
act test. All statistical analyses were performed using
SPSS version 14 (SPSS Inc., Illinois).
3. Results
3.1. Disease outcome
Survival of the patients was examined using the
Kaplan-Meier method and survival differences were
analyzed using the log-rank (Mantel-Cox) test. Tests
of equality of survival distributions for the different
















Fig. 1. Cumulative survival rate of patients with NSCLC whose samples were used in this study (survivalM – survival in months,+ – censored
data).
cancer types (Chi= 0.351 andp = 0.839) and tumour
location (Chi= 2.655,p = 0.753) were not statistically
significant (Figs 1 and 2).
Elevated expression of COX-2 was observed in
60.0% of tested NSCLC (61.8% in ADC, 27.3% in
LCC and 66.7% in SCC, Table 3) and hTERT in 55.6%
(61.7% in ADC, 27.3% in LCC and 57.8% in SCC).
Average overall∆∆CT for COX-2 in NSCLC was 5.3
(SD± 0.6) and average overall∆∆CT for hTERT 8.2
(SD± 0.9).
Using Cox’s regression model with multiple vari-
ables, no statistically significant association between
survival and observed expression in COX-2 (p = 0.187)
and in hTERT (p = 0.552) was found. There was also
no statistically significant association between muta-
tion in K-RAS (p = 0.554) or P53 (p = 0.963) and
patient survival.
3.2. Mutational screening
We detected 36 P53 alterations in 31 NSCLC tu-
mours (one ADC and two SCC samples with 2 al-
terations), 5 of them to our knowledge published for
the first time; 470490 del (V157fs), 757758delAC
(T253fs), 875919 del + del 25 (K292fs), S362N
(AGC>AAC), 1056-1100del+ del 14 (D352fs). Three
(8.3 % NSCLC) of the detected mutations were silent;
all others resulted in a change of amino acid (63.9%
NSCLC), or in frame shift or abbreviation of the
p53 protein (27.0% NSCLC). Twenty-five percent of
the mutations are transitions and 50.0% transversions,
55.6% of all transversions are G>T changes (Ta-
ble 4). Codon V157 is the target of the mutation
4 times, codons G245, R283 three times and codon
R273 twice (Table 4). Of all frame shift mutations
(22.2% of all mutations found in P53), 62.5% result
in a premature stop codon. We also found one G>T
transversion, which causes an E204X change (Table 4).
Mutations causing a premature stop of translation
are K139fsX169, H178fsX180, E204X, N239fsX239,
T253fsX262, E285fsX304 and P301fsX305. Four dif-
ferent mutations were found in two and mutation R283P
in 3 tumours (Table 4). P53 was mutated in 26.5%
ADC, 27.3% LCC and 55.6% SCC. In terms of fre-
quencies of mutations found in P53, 69.4% of all mu-
tations were found in SCC (Table 5). The frequency of
P53 mutation was significantly different between SCC
and ADC (Fisher’s exact test,p = 0.0122).
K-RAS mutations were found in 13 NSCLC tu-
mours; all had been previously described at codon hot-
spots (codons: 12 (76.9%), 13 (15.4%) and 61 (7.7%))
and all were missense (Table 4). Of all mutations,
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Table 3
Average overall results∆∆CT for expression levels of COX-2 and hTERT genes for
different types of NSCLC. (COX-2 and hTERT expression results refer to the relative
quantification of mRNA levels of the target genes. Results are the quantity of transcripts
of COX-2 and hTERT mRNAs in tumour samples relative to normal tissues, determined
using the∆∆CT (∆CT tumour -∆CT normal) method;∆∆CT; relative comparative
cycle threshold number for quantification of mRNA levels of the target genes). The
expression of COX-2 and hTERT was higher in all tumours regardless of the NSCLC
type
Lung cancer type ADC LCC SCC
Average overall CT COX-2 8.9 (SD± 0.9) 2.3(SD± 0.1) 3.0 (SD± 0.2)
















Fig. 2. Cumulative survival rate of patients with different types of NSCLC whose samples were used in this study (black – LCC, dark grey –
ADC, light gray – SCC; survivalM – survival in months,+ – censored data).
23.1% were G>T transversions. G12A was detected
in two ADC and in one LCC sample. G12R and G12D
were detected in two samples. K-RAS was mutated in
27.0% ADC, 18.2% LCC and in 2.2% SCC. In terms
of frequencies of mutations, we found 76.9% of all
mutations in K-RAS in ADC (Table 5). In 12 cases,
the affected aminoacid was glycine and in one case
glutamine (Table 4). Fisher’s exact test showed a sta-
tistically significant difference in frequency of K-RAS
mutations between ADC and SCC (p = 0.035).
Mutation detection in the COX-2 gene resulted in
the detection of 3 different alterations not to our knowl-
edge previously published. V102V (GTG>GTC) was
found in SCC, H212H (CAT>CAC) in ADC and P593L
(CCC>CTC) in two LCC tumours. Both patients with
those mutations were male and their survival was less
than 2 months. All detected alterations were heterozy-
gous and detected only in tumours. The distribution
of overall mutations showed that the majority of muta-
tions were found in SCC (Table 5), although there are
differences in the frequencies of mutations in different
types of NSCLC.
3.3. Comparisons between different parameters
For statistical evaluation of the relationship between
hTERT and COX-2 expression, patient survival, stag-
ing, age at diagnosis in overall NSCLC patients, we
used Spearman’s Rho test statistic. A significant pos-
itive correlation was found between expression of
COX-2 and hTERT (p < 0.001) and hTERT expres-
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Table 4
Mutations found in P53 and K-RAS genes in non-small cell lung tumours according to
the type and position. (No. of mutations – number of different types of mutations, and
percentage of all mutations found in P53 or K-RAS genes; Other* – inframe deletion of
three base pairs; V157-3 missense mutations resulting in change of aminoacid, and one
deletion of the codon; R273 – 2 SCC tumours with R273H mutation, R283 – mutation
R283P was detected in one ADC, one LCC and one SCC)
Mutations in P53 No. of mutations Mutations in K-RAS No. of mutations
Transitions 9 (25.0%) Transitions 3 (23.1%)
Transversions 18 (50.0%) Transversions 10 (76.9%)
Other 9 (25.0%) Other 0
SUM 36 (100%) SUM 13 (100%)
Silent mutations 3 (8.3%) Silent mutations 0
Missense mutations 23 (63.9%) Missense mutations 13 (100%)
Other* 1 (2.8%) Other* 0
Change in RF 8 (22.2%) Change in RF 0
Nonsense 1 (2.8%) Nonsense 0
SUM 36 (100%) SUM 13 (100%)
V157 4 (11.1%) G12 10 (76.9%)
G245 3 (8.3%) G13 2 (15.4%)
R273 2 (5.6%) Q61 1 (7.7%)
R283 3 (8.3%)
Other mutations 24 (66.7%) Other mutations 0
SUM 36 (100%) SUM 13 (100%)
Table 5
Distribution of mutations in P53, K-RAS and COX-2, detected in squamous
carcinoma, adenocarcinoma and large cell carcinoma. Percentages show
fractions of the mutations in one type of cancer versus the total mutations
found in a particular gene (SCC – squamous cell carcinoma, ADC – ade-
nocarcinoma, LCC – large cell carcinoma, NSCLC – non-small cell lung
cancer)
Mutations found SCC ADC LCC NSCLC
P53 25 (69.4%) 8 (22.2%) 3 (8.4%) 36 (100%)
K-RAS 1 (7.7%) 10 (76.9%) 2 (15.4%) 13 (100%)
COX-2 1 (25.0%) 1 (25.0%) 2 (50.0%) 4 (100%)
All 27 (50.9%) 19 (35.8%) 7 (13.2%) 53 (100%)
sion and staging (p < 0.05). A significant negative
correlation was found between hTERT expression and
survival (p < 0.01). We also determined that although
staging showed no correlation with survival (p = 0.05),
pN was negatively correlated with survival (p < 0.01)
and pM with age at diagnosis (p < 0.05).
The Mann-Whitney test (exact 2-tailedσ) for in-
vestigating possible differences between groups with
mutations in P53 and/or K-RAS and between different
cancer types was used. COX-2 expression was highly
significant in ADC (p < 0.01) and in SCC (p < 0.01).
hTERT expression was also highly significant in ADC
(p < 0.01) and SCC (p < 0.05). Comparisons between
groups with P53 and K-RAS showed positive correla-
tion between COX-2 expression and K-RAS mutations
(p < 0.05; Fig. 3). The Mann-Whitney test was also
performed for differentiation between genders. hTERT
and COX-2 expression was found to be significantly
higher in females (p < 0.05, Fig. 4).
4. Discussion
We examined the relationships between somatic mu-
tations in P53 and K-RAS and expression of COX-2
and hTERT, in order to investigate the specific associ-
ations between these alterations and clinical data (sur-
vival, age at diagnosis, histology, staging) in NSCLC
overall and in all three types of NSCLC independent-
ly. Each marker has already been studied as a prog-
nostic factor based on the roles in carcinogenesis and
frequencies of alterations found in lung cancer [12,15,
21]. There are also published studies of the association
between two or more of the above studied markers [18,
22–24]. We analysed 90 patients with complete infor-
mation for four biomarkers and histological and clini-
cal data. Our major findings are as follows. We could
not predict survival or test the variables with the COX
regression model with clinicopathological data (stag-
ing, type of lung cancer, location of tumour, gender

















Fig. 3. Box-plot chart of the association of COX-2 expression and K-RAS mutation, within the NSCLC group (+ – group of NSCLC tumours
with K-RAS mutation,− – group of NSCLC tumours without mutation). It shows that K-RAS mutations positively correlate with higher COX-2
expression.
and age at diagnosis) and the four analysed biomarkers.
Patient survival was also examined using the Kaplan-
Meier method and survival differences were analyzed
using the log-rank (Mantel-Cox) test; distributions for
the different cancer types and tumour location were not
statistically significant. The lack of significance could
be due to the small number of patients with a specific
type of lung cancer (for example 11 patients with large
cell carcinoma) or the overall number of patients (90
patients were included in the study), although the ab-
sence of prognostic significance of NSCLC when test-
ing different variables with the COX proportional mod-
el has already been published on a much larger patient
group [23]. One possibility is that variables and clin-
icopathological data together are less informative for
prediction of survival but they could still be associat-
ed, so we used two other appropriate test statistics for
determination of the association.
The results of Spearman’s test showed a positive
correlation between COX-2 and hTERT expression, as
already described by Lu et al. [22], and between hTERT
and staging. We also proved a negative correlation
between survival and hTERT expression. There is also
an interesting result concerning staging and testing pT,
pN and pM independently. Although staging showed
no correlation with survival and age at diagnosis, if
tested separately and independently, pN correlated with
worse survival and pM with earlier age at diagnosis.
pT in our case showed no significant correlation with
survival and age at diagnosis.
Mutation screening of the P53 and K-RAS revealed
high mutation frequencies. The frequency of P53 mu-
tation in different NSCLC types was significant only
for squamous cell carcinoma. The mutational pattern
was very heterogeneous, mutations occurred at 29 dif-
ferent codons and only 4 mutations occurred more than
once. Nevertheless, the conserved domain of the gene
was still the most frequent target of the mutation. Ac-
cording to data obtained about the smoking status of the
studied patients, 86.7% of the patients were smokers
or former smokers (89.3%) male and 73.3% female).
It is known that the polycyclic aromatic hydrocarbons
(PAHs) of tobacco smoke carcinogens primarily cause
G>T transversions, whereas nitrosamines causes G>A






































Fig. 4. Box-plot charts of the association between gender and hTERT and COX-2 expression. The associations between gender and higher
expression of hTERT and COX-2 are significant for female patients (p < 0.05).
transitions at non CpG sites in the P53 gene [25,26]. We
found that 55.6% of all transversions are G>T transver-
sions, mostly changing codons that are known as the
strongest binding sites for PAHs [26]. The codons most
frequently affected by mutations are V157 (11.1% of
all mutations), G245 (8.3% of all mutations) and R283
(8.3% of all mutations). The V157 and G245 sites are
described as hotspot codons [26], but not R283. R283,
found in one of every type of NSCLC studied, is not
related to smoking status. The overall frequency of
smoking related mutations found in P53 is in general
accordance with the percentage of smokers included
in our study, however, as previously established un-
known exposure, geographical differences, and/or eth-
nicity of the patients may also influence P53 mutation
spectra [25–27].
Three different mutations were discovered in the
COX-2 gene, but only one (detected in two large-cell
cancers) was missense. The frequency of mutations
in K-RAS was significant for adenocarcinoma, which
has already been recognised [27,28]. We found 13
mutations (all missense and mostly at codon-hotspot
G12; 76.9% of all mutations). Out of all mutations in
K-RAS, 23.1% were G>T transversions, which is less
than already published [27,28]. That could arise from
population differences, and the fact that ADC is the
type of cancer, which is related to women and never
smokers.
All mutations can alter the exonic splicing enhancers
(ESEs), which participate in alternative and constitu-
tive splicing [29]. P53 has 14 significant ESE mo-
tifs, according to Gorlov et al., and in our case 16 out
of 36 (44.4%) of all mutations discovered in P53 al-
ter one of four putative significant ESE motifs [30].
ESEs are mostly altered by missense mutations (87.5%
of all ESE altering mutations), but we also discovered
one deletion and one insertion in a putative ESE re-
gion. Using ESE Finder version 3.0 for prediction of
ESE sites in P53 we discovered that all but 2 muta-
tions were altering putative ESE sites [31]. The high
number of mutations altering putative ESEs found was
to be expected (considering that over 140 ESE motifs
are in the ORF of the P53 gene and that, according to
previous publication 71% of all missense mutations hit
ESE sites) [30]. We also confirmed the previously pub-
lished finding that missense mutations do co-localise
with ESEs motifs in the P53 gene, and when analysing
the K-RAS gene, we discovered that missense muta-
tions of G12 and G13 co-localise with 2 ESEs. A puta-
tive ESE responsive to SC35 is altered by 11 out of 13
missense mutations found (84.6%) and ESE responsive
to SRp55 by 2 out of 13 missense mutations. Missense
mutations therefore strongly associate with ESE motifs
(Chi squarep < 0.05 for both genes) in P53 and K-RAS
genes and could give a new perspective on the func-
tions of mutations in the coding regions of these genes.
There are two possible explanations for the association;
either mutations arise more frequently in ESE, or muta-
tions in ESE are generally more pathogenic than those
outside ESEs, and therefore more likely to be detected
in tumours [30]. It must nevertheless be emphasized
that the presence of a high-score motif in a sequence
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does not necessarily identify a functional ESE, but only
predicts the possibility of one [31].
Comparison between groups with P53 and K-RAS
mutations and those without revealed a strong correla-
tion between K-RAS mutation and COX-2 expression.
It was shown that COX-2 expression is regulated via
the Ras signalling pathway, and induction of mutated
K-RAS rapidly increases COX-2 levels [32]. A correla-
tion of K-RAS mutations with gastric cancer, colorectal
cancer and K-RAS mutated lung cancer cell lines has
already been shown [32–34], but this is the first time
K-RAS mutations have been linked to COX-2 expres-
sion in NSCLC tumours. We did not find any corre-
lation between P53 mutations and COX-2 or hTERT
expression. Although some publications associate P53
status with telomerase or COX-2 expression [16,18]
other investigations have concluded that telomerase dis-
orders and COX-2 activity are possibly independent of
P53 mutations [22–24]; and it has already been proven
that evaluation of p53 accumulation is not always com-
parable with P53 mutational status [5,35,36].
High expression was proven not to be a consequence
of staging but of gender (p < 0.05). The Mann-Whitney
U test showed no correlation between gender and stag-
ing and gender was also independent of survival and
mutations. Elevated expression may thus be a conse-
quence of different pathways of tumourigenesis, dif-
ferent triggers for expression of COX-2 and hTERT or
potential gender specific differences. It is also possible
that higher expressionwas the result of the predominant
ADC in female patients (38.2%), but when combined
with male patients the significance was lost. This is
the first time that gender difference has been related to
expression of COX-2 and hTERT genes.
In view of the similar clinical and biological charac-
teristics of types of NSCLC, this study provides insight
into associations among different biomarkers all com-
monly used in determination of the type, severity and
prognosis of lung cancer. It shows that some histolog-
ical and clinical features are more related to molecular
genetic results than to other data, and that the use of
different biomarkers combined with clinical and histo-
logical data, could result in a loss of prognostic power,
although strong relations do exist between the different
variables analysed.
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